Health 2.0 Europe 2011 is Accepting Speaker Submissions

Following the success of the first event in Paris in April 2010, the 2nd annual Health 2.0 Europe will showcase the best of Europe's user-generated healthcare and reconvene over 500 leaders and stakeholders in Web 2.0 for health. Participants will include IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical device and pharmaceutical companies, telecom groups, VC and financiers, policy makers, and academics.

If you are in the Health 2.0 space and offer a technology or service that is particularly innovative or provides a solution to a major healthcare challenge, Health 2.0 wants to hear from you! In general, most of the programming consists of panels with speakers showing their technology in 4-minute demos, and commentators reflecting on what they hear and how it will fit into healthcare from their perspective, followed by interaction with the demonstrators.

Themes for 2011 will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion, behavior change and Wellness 2.0
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Cloud computing and unplatforms

More information on the programme is available at http://www.health2con.com/europe/.

Decisions on panelists are made by the organizers in close consultation with our Advisory Board. It is a highly selective process as the topic of the conference, audience interest, diversity of presenters and format of panels are taken into consideration.

Apply now!

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Distinct human mutations can alter the effect of m…

Every person has a unique DNA sequence in their genome. Now researchers from the University of Copenhagen and the MRC Laboratory of Molecular Biology in Cambridge have tr...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Arthritis drug could help treat advanced skin canc…

Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown. The study, ...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]